



# EFSA report on scientific assistance on control and surveillance activities

**Alessandro Broglia**

ALPHA Unit, EFSA

GFTADs, 18-19 October 2018, Ohrid

# Two main questions

1. How long vaccination to eliminate LSD
2. What surveillance system for different scenarios

- Infection status
- Vaccination status

and objectives:

- Early detection of LSD
- Demonstrate disease absence

# Vaccination duration


System used: spread model

**2 case studies:** Albania and Bulgaria/Greece

- Herd location and size
- Mean life expectancy
- Temperatures

Within-herd spread



Between-herd spread



# Assessment of vaccination duration

- Two important parameters:
  - Vaccination coverage: % vaccinated herds
  - Vaccination effectiveness: % vaccinated animals that were protected from infection under field conditions

# Vaccination coverage and effectiveness




## Example


- 29 farms
- 18 vaccinated >> coverage 62%
- 16 protected >> 88%

# Estimation of vaccination effectiveness


Bulgaria: 95%







Greece: 84%



Albania: 65%



# Vaccination duration for LSD elimination



# Vaccination duration for LSD elimination

Simulated spread in Albania

vaccination effectiveness: 65%

	2 years	3 years	4 years	5 years
VC 50%	PERSIST P=80%	PERSIST P=30%	OK	OK
VC 90%	PERSIST P=20%	OK	OK	OK



# Vaccination duration for LSD elimination

Simulated spread in Greece/Bulgaria

Coverage	VE	2 years	3 years	4 years	5 years
70%	80%	<b>PERSIST</b> P: 20%	<b>PERSIST</b> P<5%	<b>OK</b>	<b>OK</b>
	95%	<b>PERSIST</b> P<20%	<b>PERSIST</b> P<5%	<b>OK</b>	<b>OK</b>
90%	80%	<b>PERSIST</b> P<20%	<b>OK</b>	<b>OK</b>	<b>OK</b>
	95%	<b>OK</b>	<b>OK</b>	<b>OK</b>	<b>OK</b>

# Scenarios to consider for surveillance

1. No infection, no vaccination
2. No infection, vaccination is continued
3. No infection, vaccination is stopped
4. Past infection, vaccination is stopped

# Elements assessed for surveillance

- objective of the surveillance
- type of surveillance
- possible source of infection
- susceptible target population
- risk areas
- risk period
- diagnostic tests
- design prevalence or threshold of detection.
- sample size
- sampling frequency

# Surveillance design for early detection

Key issue: estimate design prevalence for early  
detection and sampling frequency

Or

How to detect LSD in the **quickest way** in order to  
**minimise losses**

LSD spread model: 3 possible uses >>>>>

# Sampling frequency for early detection

Model used to predict time to detection and sampling frequency

**Table 3:** Impact of season on predicted time to detection (in days) and related number of infected herds at detection of lumpy skin disease outbreaks

Time of incursion	Median time to detection (95% prediction interval)	Median percentage of infected herds at detection (95% prediction interval)
<b>Albania</b>		
<b>1 January</b>	75 (14–134)	0.0025 (0.0005–0.011)
<b>1 April</b>	30 (0–77)	0.0015 (0.0005–0.006)
<b>1 July</b>	15 (0–110)	0.0015 (0.0005–0.0205)
<b>1 October</b>	48 (4–75)	0.0065 (0.0005–0.0255)
<b>Bulgaria and Greece</b>		
<b>1 January</b>	62 (36–160)	0.015 (0.001–0.072)
<b>1 April</b>	21 (0–107)	0.004 (0.001–0.041)
<b>1 July</b>	22 (0–141)	0.004 (0.001–0.042)
<b>1 October</b>	45 (6–77)	0.027 (0.001–0.096)

In 2017, there were 198,000 cattle herds in Albania and 88,000 in Bulgaria and Greece, considered together.

# Prevalence at different time to detection

**Table 4:** Median (95% prediction interval) percentage of herds infected at detection when detection occurs 21, 28 or 35 days after an incursion or re-emergence of infection upon arrest of vaccination

Scenario	Time to detection <sup>(a)</sup>		
	21 days	28 days	35 days
<b>Albania, incursion in June</b>	0.003 (0.0005–6.5)	0.009 (0.0005–20.1)	0.21 (0.0005–35.1)
<b>Albania, re-emergence (2 years of vaccination, 50% coverage)</b>	0.032 (0.0007–0.15)	0.048 (0.0007–0.23)	0.12 (0.0027–0.55)
<b>Albania, re-emergence (3 years of vaccination, 50% coverage)</b>	0.023 (0.0005–0.20)	0.055 (0.0005–0.43)	0.20 (0.0005–1.4)
<b>Albania, re-emergence (2 years of vaccination, 90% coverage)</b>	0.026 (0.0005–0.066)	0.049 (0.005–0.11)	0.12 (0.0005–0.31)
<b>Bulgaria and Greece, incursion in June</b>	0.0045 (0.0011–2.9)	0.015 (0.0011–9.6)	0.074 (0.011–6.7)
<b>Bulgaria and Greece, re-emergence (2 years of vaccination, 70% coverage, 80% effectiveness)</b>	0.016 (0.0045–0.28)	0.025 (0.0045–0.54)	0.032 (0.0057–0.97)
<b>Bulgaria and Greece, re-emergence (2 years of vaccination, 70% coverage, 95% effectiveness)</b>	0.011 (0.0023–0.69)	0.016 (0.0023–1.6)	0.041 (0.0023–2.9)
<b>Bulgaria and Greece, re-emergence (2 years of vaccination, 80% coverage, 95% effectiveness)</b>	0.020 (0.0011–0.065)	0.029 (0.0023–0.17)	0.042 (0.0011–0.34)

# Time to detection at given prevalence

**Table 5:** Median (95% prediction interval) time (days)<sup>(a)</sup> to reach design prevalence after an incursion or a vaccination campaign has stopped


Scenario	Design prevalence		
	0.1%	1%	5%
<b>Albania, incursion in June</b>	35 (12–97)	38 (16–104)	43 (20–110)
<b>Albania, re-emergence (2 years, 50% coverage)</b>	34 (14–81)	54 (40–102)	77 (60–125)
<b>Albania, re-emergence (3 years, 50% coverage)</b>	31 (15–97)	45 (34–111)	60 (46–125)
<b>Albania, re-emergence (2 years, 90% coverage)</b>	35 (28–220)	54 (44–338)	74 (62–112)
<b>Bulgaria and Greece, incursion in June</b>	36 (10–118)	47 (18–93)	56 (24–111)
<b>Bulgaria and Greece, re-emergence (2 years, 70% coverage, 80% effectiveness)</b>	51 (14–75)	88 (36–143)	116 (64–139)
<b>Bulgaria and Greece, re-emergence (2 years, 70% coverage, 95% effectiveness)</b>	47 (8–147)	75 (25–358)	89 (43–151)
<b>Bulgaria and Greece, re-emergence (2 years, 80% coverage, 95% effectiveness)</b>	45 (25–95)	70 (45–124)	90 (66–140)

# Diagnostic tests

		Sensitivity	Specificity
<b>Clinical detection</b>		75%	
<b>PCR</b>	<b>blood</b>	90-100%	96-100%
	<b>Skin lesion</b>	95-100%	100
<b>ELISA</b>	<b>Experiment</b>	83%	99.7%
	<b>Field</b>	59%	99.7%
<b>Immunoperoxidase monolayer assay</b>	<b>Experiment</b>	100%	100%
	<b>Field</b>	53%	100%





# Diagnostic window



# Buffer zone : probability of LSD «escape»

planning risk based surveillance





HERDS	Total	50 km	62km	80 km
Number	90,000	3100	5400	12,500
%		3.4%	6%	13%

# Surveillance for early detection: example

- Test : clinical detection >> Se 75% (PCR confirmation)
- Sample area: area at risk (buffer zone)
- Target population: susceptible cattle population in the at risk area
- Active surveillance on areas at risk + passive surveillance on the whole country.
- Design prevalence at different times to detection
- Sampling frequency: 5 weeks
- Sample size at different design prevalence and buffer zones

synoptic table on surveillance at:

<https://doi.org/10.5281/zenodo.1451440>

# Sample size for early detection

- Example: population size: 90,000 herds in naive country

		Buffer size		
Design prevalence	Delay in detection	80 km (0.1%)	62 km (1%)	50 km (5%)
0.0045%	21 days	8000	4140	n.a.
0.075%	35 days	681	360	427
1%	47 days	51	27	31
5%	56 days	9	5	5

Sample size calculator tools: <http://efsa.openanalytics.eu>


# Demonstration of disease absence

## Serology

- Design prevalence >> % ever infected herds (e.g. 3.5%)
- Test : ELISA >> Se: 83%
- Sampling period: after major risk period (April-October)
- Sample area: whole country
- Target population: Non-immunised fraction of cattle population
- Sample size: population+ Se+ design prevalence

synoptic table on surveillance at:  
<https://doi.org/10.5281/zenodo.1451440>

# Design prevalence for demonstration of disease absence



- E.g.:
- Population size: 90,000
  - Sample size: 103 herds

# Results based on spread model

- Main characteristics of the model
  - Kernel: distance dependent
  - Herd size dependent
- Assumptions/limitations:
  - No info on vector movevement
  - No info on animal movements
  - No transmission mechanisms, just distance related



# Keep in mind!

- Monitor vaccination campaign >> **vacc. effectiveness**
- Passive surveillance: key for early warning for LSD
- areas bordering endemic regions and areas previously infected >> active surveillance
- Feasibility of surveillance for early detection: adapt it
- Data gaps:
  - ✓ within-herd transmission
  - ✓ duration of immunity vectors
  - ✓ diagnostic test performances, under field conditions
  - ✓ exact farm location and type

Thank you for your attention !


EFSA Report available at:

<http://www.efsa.europa.eu/en/press/news/181016>





# Farm size



**Figure 6:** Distribution of farm size of the total cattle population in the affected countries